Efficacy and infection morbidity of front‐line immuno‐chemotherapy in follicular lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Haematology"
DOI: 10.1111/ejh.13486
Abstract: Current UK standard of care in frontline advanced stage (III or IV) symptomatic follicular lymphoma (FL) is immuno-chemotherapy with anti-CD20 monoclonal antibodies (mAbs) rituximab (R) or obinutuzumab (O), in combination with cyclophosphamide, vincristine and prednisolone… read more here.
Keywords: efficacy infection; immuno chemotherapy; follicular lymphoma;